Navigation Links
Beckman Coulter Announces Third Quarter 2007 Results
Date:10/30/2007

$198.6 $180.3

Accrued expenses 408.7 387.9

Income taxes payable 7.1 60.9

Notes payable 25.5 73.2

Current maturities of long-term debt 12.6 9.3

Total current liabilities 652.5 711.6

Long-term debt, less current maturities 888.9 952.0

Deferred income taxes 98.1 110.1

Other liabilities 401.2 363.7

Total liabilities 2,040.7 2,137.4

Commitments and contingencies

Stockholders' equity

Preferred stock - -

Common stock 6.8 6.8

Additional paid-in capital 510.7 488.0

Retained earnings 1,212.4 1,076.4

Accumulated other comprehensive loss (21.6) (55.4)

Treasury stock, at cost (298.4) (361.5)

Common stock held in grantor trust, at cost (17.5) (16.8)

Grantor trust liability 17.5 16.8

Total stockholders' equity 1,409.9 1,154.3

Total liabilities and stockholders'

equity $3,450.6 $3,291.7

BECKMAN COULTER, INC.

KEY PRODUCT AREA AND GEOGRAPHICAL REVENUE

(in millions)

(unaudited)

Three Months Ended Nine Months Ended

September 30, 2007 September 30, 200
'/>"/>

SOURCE Beckman Coulter, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... transplant rejection occurs when the transplant recipient,s immune system ... it. It was previously thought that T cells, the ... by molecules known as chemokines in order to migrate ... Journal of Clinical Investigation , Fadi Lakkis and ... demonstrate that chemokine stimulation of T cells is not ...
(Date:5/17/2013)... The new Public-Private Partnership (PPP) in ... association’s recent annual meeting drew praise from community leaders ... who called the action “a huge step forward … ... European innovation.” , The Board of Stakeholders voted to ... PPP at its 29 April meeting in Brussels, which ...
(Date:5/17/2013)... May 17, 2013  Cellular Biomedicine Group (OTCQB: ... enrollment of the total projected enrollment required for ... and preliminary efficacy of the medical technology haMPC ... Osteoarthritis (KOA). To date the trial has had ... The Phase I open label clinical research trial ...
(Date:5/17/2013)...  Insero Health, Inc., a company developing natural compounds ... neurological disorders, is today reporting top-line results from a ... patients with drug-resistant epilepsy.  The data are being presented ... meeting by Dr. Steven Schachter , ... Advisory Board.  In this study, INS001 appeared safe and ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... Sonia Moralejo Garca at the University of the Basque Country ... and other magnetic devices of wide industrial application. , It ... that are ever smaller and that nanotechnology, although it its ... in our society. Who has not heard of nanotubes, nanoparticles ...
... INCREASE 14.6%. Q4 2007 DILUTED EPS UP 20.8% TO $.64. 2008 ... $2.62 PER SHARE., ST. LOUIS, Feb. 12 , HIGHLIGHTS: ... -- Q4 2007 Sales Set New Quarterly Record: At $532.1 ... high, beating the Q2 2007 record of $507.5 ...
... of Dow AgroSciences Announces Milestone in Wall Street ... ,Dow AgroSciences LLC and Sangamo BioSciences, Inc. (Nasdaq: ... a key research milestone as part of,their joint ... successful application of Sangamo,s zinc finger DNA-binding,protein nuclease ...
Cached Biology Technology:A researcher of UPV/EHU has designed nanomagnets for industry 2Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 2Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 3Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 4Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 5Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 6Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 7Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 8Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 9Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 10Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 11Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 12Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 13Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 14Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 15Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 16Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 17Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 18Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 19Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 20Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration 2Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration 3Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration 4
(Date:5/18/2013)... FL (May 18, 2013) Research presented at ... managing digestive health through diet and lifestyle. ... plagued by reduced muscle strength, fatigue and poor ... when patients are in remission. A randomized, double ... that vitamin D supplementation corresponded to significant relief ...
(Date:5/17/2013)... provide the white noise of the South, but the night ... Southern air hangs heavy from the humidity and the sounds ... 140 species of frogs, toads and salamanders, is the center ... and swamps are the auditorium for their symphonic choruses, the ... Initiative, or ARMI, have front-row seats. , Amphibians, ...
(Date:5/17/2013)... proteins in the brain responsible for protecting nerve cells ... increase cell survival. , The discovery, made by researchers ... the EMBO journal with additional comment in ... stroke and other brain diseases. , The research builds ... protein, known as SUMO, responsible for controlling the chemical ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4SUMO wrestling cells reveal new protective mechanism target for stroke 2
... A new study, led by Felix Aigner, M.D., ... as potentially responsible for regulating the body's inflammatory ... complications involved with many transplantations is the damage ... following surgery, known as ischemia and reperfusion (IR). ...
... major role in deadly prion diseases by smashing up ... allow fatal brain illnesses to quickly spread, new Brown ... say, because they might reveal a way to control ... drug could be made that inhibits this fragmentation process, ...
... The costs due to complications from preterm birth are ... preterm infants are estimated to be almost $2 billion ... researchers found that giving nitroglycerin to mothers who had ... baby’s health. The results of the study are reported ...
Cached Biology News:Brown team finds crucial protein role in deadly prion spread 2
...
Rat Antibody to Kinase Suppressor Of Ras Recognises the kinase suppressor of Ras (KSR). Immunogen: Recombinant human KSR protein Specificity: human kinase supressor of Ras...
Request Info...
NATIVE RAT OSTEOCALCIN...
Biology Products: